ATRA
HEALTHCAREAtara Biotherapeutics Inc
$5.15+0.39 (+8.19%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ATRA Today?
No stock-specific AI insight has been generated for ATRA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.92$19.14
$5.15
Fundamentals
Market Cap$44M
P/E Ratio2.0
EPS$2.57
Dividend Yield—
Dividend / Share—
ROE-20.2%
Profit Margin0.3%
Debt / Equity—
Trading
Volume185K
Avg Volume (10D)—
Shares Outstanding8.5M
ATRA News
39 articles- ATRA Upgraded by Canaccord Genuity -- Price Target Raised to $13GuruFocus·May 8, 2026
- FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline AliveAdvfn·May 7, 2026
- Atara Biotherapeutics Provides Regulatory Update on TabelecleucelYahoo Finance·May 7, 2026
- Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRAGlobeNewswire Inc.·Apr 28, 2026
- Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) Urged to Join Class Action – Contact Levi & Korsinsky to Learn MoreGlobeNewswire Inc.·Apr 27, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 27, 2026
- ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRAGlobeNewswire Inc.·Apr 25, 2026
- Atara Biotherapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights – ATRAGlobeNewswire Inc.·Apr 20, 2026
- Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitGlobeNewswire Inc.·Apr 20, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 20, 2026
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRAGlobeNewswire Inc.·Apr 18, 2026
- ATRA Shareholder Alert: May 22, 2026 Lead Plaintiff Deadline in Atara Biotherapeutics, Inc. Securities Class Action Lawsuit — The Gross Law FirmGlobeNewswire Inc.·Apr 17, 2026
- ROSEN, A TOP RANKED LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRAGlobeNewswire Inc.·Apr 12, 2026
- ROSEN, A LEADING NATIONAL FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRAGlobeNewswire Inc.·Apr 9, 2026
- ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff RoleGlobeNewswire Inc.·Apr 7, 2026
- Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) should contact Levi & Korsinsky about pending Class Action - ATRAGlobeNewswire Inc.·Apr 6, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 6, 2026
- ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRAGlobeNewswire Inc.·Apr 4, 2026
- Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant ExerciseYahoo Finance·Apr 3, 2026
- Rajani Dinavahi, MD, Appointed Chief Medical Officer of ArdelyxGlobeNewswire Inc.·Apr 1, 2026
- Did You Lose Money Investing in Atara Biotherapeutics, Inc.? Robbins LLP Encourages Investors with Significant Losses to Contact the Firm About Their Rights Against ATRAGlobeNewswire Inc.·Apr 1, 2026
- ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRAGlobeNewswire Inc.·Mar 28, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Mar 26, 2026
- Atara Biotherapeutics: Q4 Earnings SnapshotYahoo Finance·Mar 16, 2026
- Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational ProgressYahoo Finance·Mar 16, 2026
- Pierre Fabre seeks to revive US approval chances for spurned cell therapyBiopharmadive·Mar 3, 2026
- Atara Biotherapeutics Provides a Business UpdateYahoo Finance·Feb 23, 2026
- Top Midday DeclinersYahoo Finance·Jan 13, 2026
- Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)Yahoo Finance·Jan 12, 2026
- AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectationsBiopharmadive·Jan 12, 2026
- Epstein Barr Virus Research Analysis Report 2025-2035: Market Led by AstrViracta, Atara, AlloVir, and Pierre Fabre as Antiviral and Immune-Modulating Therapy Innovation AcceleratesYahoo Finance·Nov 18, 2025
- Atara Biotherapeutics: Q3 Earnings SnapshotYahoo Finance·Nov 12, 2025
- Atara Biotherapeutics Announces Third Quarter Financial Results and Operational ProgressYahoo Finance·Nov 12, 2025
- Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue EstimatesYahoo Finance·Nov 10, 2025
- Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains?Yahoo Finance·Nov 7, 2025
- Pacira (PCRX) Tops Q3 Earnings EstimatesYahoo Finance·Nov 6, 2025
- Adma Biologics (ADMA) Q3 Earnings Match EstimatesYahoo Finance·Nov 5, 2025
- Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)Yahoo Finance·Nov 3, 2025
- While institutions own 28% of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), individual investors are its largest shareholders with 35% ownershipYahoo Finance·Oct 3, 2025
All 39 articles loaded
Price Data
Open$4.77
Previous Close$4.76
Day High$5.26
Day Low$4.72
52 Week High$19.14
52 Week Low$3.92
52-Week Range
$3.92$19.14
$5.15
Fundamentals
Market Cap$44M
P/E Ratio2.0
EPS$2.57
Dividend Yield—
Dividend / Share—
ROE-20.2%
Profit Margin0.3%
Debt / Equity—
Trading
Volume185K
Avg Volume (10D)—
Shares Outstanding8.5M
About Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc., a commercially available T-cell immunotherapy company, develops treatments for cancer patients, autoimmune and viral diseases in the United States. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—